Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital upgrades Boohoo to 'hold' after shares tank

(Sharecast News) - Shore Capital has upgraded its stance on Boohoo from 'sell' to 'hold' following a big slump in the fast fashion retailer's share price over recent months. The broker said that, despite the market backdrop being poor - consumer confidence is still low, inflation is having an impact on spending and concerns remain about the fallout from America's trade war - downside is now limited after a 35% drop in the stock since November.

"While we believe that the group could face challenges from a tough macro backdrop, the focus on the Debenhams model could yet provide a more sustainable solution, for which further details are expected during the full-year results," Shore Capital said.

Boohoo said last month that it is to push ahead with plans to rebrand as Debenhams despite opposition from its largest shareholder Frasers Group - a move which Shore Capital said is "sensible".

"By focusing more on a marketplace model, it provides an opportunity for better profitability (management guides to a 20% EBITDA margin for the Debenhams division over the medium-term vs 6-8% margin for Youth brands and double-digit for Karen Millen)," the broker said.

"However, the profile of this profit development remains uncertain, and there remains a negative mix impact from other brands; therefore, we retain some caution while restructuring occurs."

Boohoo shares were up 4% at 20.6p by 1057 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.